Third, mutations in Cbl-proto-oncogenes (homologous to Cbl-c, or CBL2) are associated with changes in cancer risk in humans and mutations in related genes increase the ability to fight off tumours in mice17. This evidence concerns the gene CBLC and neoplasm.